Friday, August 22, 2014 12:50:09 PM
News/Announcements
•8/19/2014 - J3 is pleased to announce that Mr. Neal Egan has been appointed to the Board of Directors. Mr. Egan is experienced in the management, planning, coordination, implementation and oversight of marketing and sales activities for a 300-person plus technical firm. During Mr. Egan’s 52 year engineering/management career he has performed design, test, and analysis in the development of major weapon systems (Minuteman missile, M1 Main Battle Tank, and others). In addition, Mr Egan managed teams developing technologies for energy and environmental applications for both the Department of Energy and the Department of Defense for defense. Mr. Egan’s education and experience enables him to successfully interact with prospective and present clients at the decision-maker level, and with the top-levels of corporate management. He has been responsible for coordinating new projects including funding identification and capture, successfully obtaining nearly $300M of directed contract funds for his former employers.
Mr. Egan often represents his employers by working directly with present and potential federal government clients as well as those involved in federal legislative budgeting. Responsibilities included identifying business opportunities and coordinating bid responses, proposal preparation and submittal including pricing, contract negotiations and monitoring customer satisfaction during job performance.
Neal served 15 years as PAC (Political Action Committee) Chairman and was responsible for managing employee contributions, and determining their distribution. In addition, Neal was also responsible for liaison activities with federal congressional representatives, lobbyists and with the Western Governor's Association.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM